Daiichinkyo CoDSKYF -4.91%73 EBITDA Margin % is 3.08% as of Mar. 2026, which is 80% below its 10-year median of 15.43. GuruFocus rates DSKYF with a GF Score™ of 73/100 and a GF Value™ of $40.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Daiichinkyo Co ranks better than 59.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Daiichinkyo Co's EBITDA for the
three
months ended in Mar. 2026 was $115 Mil. Daiichinkyo Co's Revenue for the
three
months ended in Mar. 2026 was $3,716 Mil. Therefore, Daiichinkyo Co's EBITDA margin for the quarter that ended in Mar. 2026 was 3.08%.
Daiichinkyo Co (OTCPK:DSKYF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Daiichinkyo Co EBITDA Margin % Related Terms
Daiichinkyo Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DSKYF vs LLY, JNJ, ABBV: EBITDA Margin % Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (DSKYF) has a EBITDA Margin % of 3.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daiichinkyo Co and its competitors. This is 80% below median its historical median of 15.43. Over the past decade, Daiichinkyo Co's EBITDA Margin % has ranged from 13.16 to 23.12. According to the industry distribution chart, Daiichinkyo Co ranks #383 out of 955 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Daiichinkyo Co's EBITDA Margin % too high?
Daiichinkyo Co's current EBITDA Margin % of 3.08% is 80% below median its 10-year median of 15.43. Over the past 10 years, this metric has ranged from a low of 13.16 to a high of 23.12. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Daiichinkyo Co's value of 3.08% is 75.1% below this industry median. Based on the distribution chart, Daiichinkyo Co ranks #383 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's EBITDA Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #383 out of 955 companies for EBITDA Margin %. This puts Daiichinkyo Co in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Daiichinkyo Co's value of 3.08% is 75.1% below this benchmark. Historically, Daiichinkyo Co's own EBITDA Margin % has ranged from 13.16 to 23.12 over the past decade. While the company's 10-year median is 15.43 vs. the industry median of 12.39, Daiichinkyo Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current EBITDA Margin % of 3.08% is 75.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current EBITDA Margin % is 3.08%, which is 80% below median its own 10-year median of 15.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (DSKYF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.31, compared to a current price of $14.76 — trading 63.4% below its estimated fair value. The current EBITDA Margin % is 3.08%, which is 80% below median its 10-year median of 15.43 and 75.1% below the Drug Manufacturers industry median of 12.39. Daiichinkyo Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Daiichinkyo Co (DSKYF), the current EBITDA Margin % is 3.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (DSKYF) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of $14.76 is trading 63.4% below its estimated GF Value™ of $40.31.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for DSKYF:
EBITDA Margin %: 3.08% (80% below median its 10-year median of 15.43)
GF Value™: $40.31 vs. price of $14.76 (63.4% below fair value)
Industry Position: 75.1% below the Drug Manufacturers median (#383 of 955)
No single metric tells the full story. See the DSKYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
73GF Score
Get the complete analysis for DSKYF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DSKYF has been successfully added to your 
